CoChat
Sign Up
Cited by 44Childhood Cancer Survivors' Quality of LifeAcute Lymphoblastic Leukemia researchGlobal Cancer Incidence and Screening

Survival after relapse in children with solid tumors: A follow‐up study from the Italian off‐therapy registry

Ceschel, Stefano, Casotto, Veronica, Valsecchi, Maria Grazia, Tamaro, Paolo, Jankovic, Momcilo, Hanau, Guia, Fossati, Franca, Pillon, Marta +5 more·2006·Pediatric Blood & Cancer
DOI 10.1002/pbc.20726
Open this paper in CoChat — free account

Abstract

Background: Despite the increased survival of children with solid tumors, a significantproportion of cases still relapse following treatment discontinuation, and knowledge about the long‐term outcome of this selected group of patients remains incomplete. Objective: To describe the long‐term outcome of children treated for a solid tumor who relapsed after the elective end of therapy, and to explore factors associated with survival. Methods: All patients with the selected diagnoses—Hodgkin disease (HD), neuroblastoma (NB), tumor of the central nervous system (CNS), Wilms tumor (WT), or soft tissue sarcoma (STS)‐enrolled in the Italian Pediatric Off‐Therapy Registry in the period 1980–1998 were evaluated. Out of 3,927 patients, 694 had relapsed after treatment suspension; 639 were available for analysis. Survival and event‐free survival were estimated by the Kaplan–Meier method. The log‐rank test was used to assess differences in survival among the various types of cancer considered. Multivariate Cox proportional hazards analysis was adopted to explore possible prognostic factors. Results: There were 335 deaths: most of them (93%) were related to the primary cancer. The overall survival rate after relapse was 38% (95% CI 33–42) at 5 years, and 32% (95% CI 27–36%) at 15 years, while event free survival was 31% (95% CI 26–35) and 26% (95% CI 22–30%), respectively. There were significant differences according to the original diagnosis, with patients with HD doing better, and those with NB, CNS, and STS worse. No improvement of prognosis was evident over time. Post‐relapse stem cell transplantation was associated with decreased risk of death only in the first year, not thereafter. Conclusions: Overall, patients with solid tumors who relapse after treatment discontinuation have a poor outcome, but significant differences exist according to the tumor types. Pediatr Blood Cancer 2006; 47:560–566. © 2006 Wiley‐Liss, Inc.

Integrity signals

Registry

Crossref · 10.1002/pbc.20726

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Ceschel, S., Casotto, V., Valsecchi, M. G., Tamaro, P., Jankovic, M., Hanau, G., Fossati, F., Pillon, M., Rondelli, R., Sandri, A., Silvestri, D., Haupt, R., & Cuttini, M.
Affiliations
  • Ospedale di San Donà di Piave (IT)
  • Agenzia Regionale di Sanità della Toscana (IT)
  • University of Milano-Bicocca (IT)
  • IRCCS Materno Infantile Burlo Garofolo (IT)
  • Istituto Giannina Gaslini (IT)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • University of Padua (IT)
  • University of Bologna (IT)
  • University of Turin (IT)
  • Bambino Gesù Children's Hospital (IT)
Corresponding author
Haupt, Riccardo
ORCID
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2006-01-04
Volume
47
Issue
5
Pages
560-566
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
DOI
10.1002/pbc.20726
OpenAlex
W1998720050
Cited by
44
References
26
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 1 · 2022: 3 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 2 · 2015: 4 · 2013: 2
FWCI
2.80
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Pediatric Blood & Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Acute Lymphoblastic Leukemia research
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
Keywords
pediatric solid tumors, tumor recurrence, long-term survival, event-free survival, prognostic factors, Hodgkin's disease, neuroblastoma, central nervous system tumors, Wilms tumor, soft tissue sarcoma
MeSH terms
Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Hodgkin Disease, Humans, Infant, Infant, Newborn, Italy, Male, Wilms Tumor, Nervous System Neoplasms, Neuroblastoma, Prognosis, Recurrence, Registries, Risk Factors, Sarcoma, Transplantation, Homologous, Cohort Studies, Survival Rate, Treatment Outcome, Disease-Free Survival, Stem Cell Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review